Home › Research › Treatments
Characterizing Clinical Progression in Cognitively Unimpaired Older Individuals with Brain Amyloid: Results from the A4 Study
Rentz DM, Rosenberg PB, Sperling RA, Donohue MC, Raman R, Liu A, Aisen PS.. The journal of prevention of Alzheimer's disease, 2024-01-01
Topic: Amyloid, tau and blood-test diagnosis
Results There were no statistical differences between the placebo or solanezumab groups in CDR-G, CDR-SB, specific CDR boxes or CDR composite scores over the course of the trial. The probability of cognitive and functional progression in CDR boxes began either at the intermediate or advanced amyloid level (46.1 to 77.2 CL, > 77.2 CL), while amyloid at the lowest level ( Conclusions The findings suggest that the CDR memory box and the CDR cognitive composite progressed over 240 weeks and were associated with intermediate and advanced stages of amyloid at baseline. These finding suggest that specific CDR box score changes may help refine our measurement of expected treatment effects in future AD prevention trials.
Key findings
- Results There were no statistical differences between the placebo or solanezumab groups in CDR-G, CDR-SB, specific CDR boxes or CDR composite scores over the course of the trial.
- The probability of cognitive and functional progression in CDR boxes began either at the intermediate or advanced amyloid level (46.1 to 77.2 CL, > 77.2 CL), while amyloid at the lowest level (< 46.1 CL) showed relatively little CDR progression.
- These finding suggest that specific CDR box score changes may help refine our measurement of expected treatment effects in future AD prevention trials.
Why it matters
In this study of cognitively unimpaired older people with brain amyloid, there were no statistical differences between the placebo and solanezumab groups on cognitive and functional measures over the trial. It suggests that specific clinical rating scale changes may help measure expected treatment effects in future prevention trials, but it shows no benefit from solanezumab.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants583
- Evidence strengthHigh
How this study scored 65/100
Published in a peer-reviewed journal, and it is a randomised controlled trial. Scored zero for effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The journal of prevention of Alzheimer's disease) |
| Journal's citation record | 0 / 4 | The Journal of Prevention of Alzheimer s Disease: journal h-index 63 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomised controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 583 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 1 / 2 | Randomised (as stated in the record) |
| Times cited | 2 / 7 | Cited 13 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.2 citations a year over 4 year(s) since 2024 |
| Impact for its field and year | 3 / 6 | Cited 3.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 4 other studies in this library |
| Still being cited | 1 / 4 | Cited 13 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Paul S. S Aisen: h-index 87 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | PubMed indexes it as a multicentre study |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39044489) |
| Free to read | 2 / 2 | Free to read |
| Total | 65 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.14283/jpad.2024.123
- PubMed: 39044489
- Original source →
- Free full text: The Journal of Prevention of Alzheimer s Disease →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
APA 7th
Rentz, D. M., Rosenberg, P. B., Sperling, R. A., Donohue, M. C., Raman, R., Liu, A., et al. (2024). Characterizing Clinical Progression in Cognitively Unimpaired Older Individuals with Brain Amyloid: Results from the A4 Study. The journal of prevention of Alzheimer's disease. https://doi.org/10.14283/jpad.2024.123
Vancouver
Rentz DM, Rosenberg PB, Sperling RA, Donohue MC, Raman R, Liu A, et al. Characterizing Clinical Progression in Cognitively Unimpaired Older Individuals with Brain Amyloid: Results from the A4 Study. The journal of prevention of Alzheimer's disease. 2024. doi:10.14283/jpad.2024.123. PMID: 39044489.
BibTeX
@article{rentz2024-39044489,
author = {Rentz, D. M. and Rosenberg, P. B. and Sperling, R. A. and Donohue, M. C. and Raman, R. and Liu, A. and Aisen, P. S.},
title = {{Characterizing Clinical Progression in Cognitively Unimpaired Older Individuals with Brain Amyloid: Results from the A4 Study}},
journal = {The journal of prevention of Alzheimer's disease},
year = {2024},
doi = {10.14283/jpad.2024.123},
pmid = {39044489},
url = {https://doi.org/10.14283/jpad.2024.123}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 15.
Later studies that cite this one
4 studies in the alzhub library list this one in their references.
Related studies in Treatments
Also in Treatments
166 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.